FI971532A - HER4, ihmisen reseptorityrosiinikinaasi, joka kuuluu ryhmään ihokasvutekijäreseptorit - Google Patents

HER4, ihmisen reseptorityrosiinikinaasi, joka kuuluu ryhmään ihokasvutekijäreseptorit Download PDF

Info

Publication number
FI971532A
FI971532A FI971532A FI971532A FI971532A FI 971532 A FI971532 A FI 971532A FI 971532 A FI971532 A FI 971532A FI 971532 A FI971532 A FI 971532A FI 971532 A FI971532 A FI 971532A
Authority
FI
Finland
Prior art keywords
her4
growth factor
tyrosine kinase
skin growth
group
Prior art date
Application number
FI971532A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI971532A0 (fi
Inventor
Gregory D Plowman
Mohammed Shoyab
Clay Siegall
Jean-Michel Culouscou
Ingegerd Hellstrom
Karl E Hellstrom
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of FI971532A0 publication Critical patent/FI971532A0/fi
Publication of FI971532A publication Critical patent/FI971532A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF] (urogastrone)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
FI971532A 1994-10-14 1997-04-11 HER4, ihmisen reseptorityrosiinikinaasi, joka kuuluu ryhmään ihokasvutekijäreseptorit FI971532A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32344294A 1994-10-14 1994-10-14
PCT/US1995/013524 WO1996012019A2 (fr) 1994-10-14 1995-10-10 Recepteur humain her4 de type tyrosine-kinase appartenant a la famille des facteurs de croissance de l'epiderme

Publications (2)

Publication Number Publication Date
FI971532A0 FI971532A0 (fi) 1997-04-11
FI971532A true FI971532A (fi) 1997-06-11

Family

ID=23259216

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971532A FI971532A (fi) 1994-10-14 1997-04-11 HER4, ihmisen reseptorityrosiinikinaasi, joka kuuluu ryhmään ihokasvutekijäreseptorit

Country Status (9)

Country Link
EP (1) EP0787187A1 (fr)
JP (1) JPH10507362A (fr)
AU (1) AU3963295A (fr)
CA (1) CA2202533A1 (fr)
FI (1) FI971532A (fr)
IL (1) IL115642A0 (fr)
MX (1) MX9702664A (fr)
NO (1) NO971686L (fr)
WO (1) WO1996012019A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999019488A1 (fr) * 1997-10-15 1999-04-22 Children's Medical Center Corporation Nouveaux recepteurs humains de l'egf et leur utilisation
AU1518799A (en) * 1997-10-31 1999-05-24 Georgetown University Medical Center Erbb-4 targeted ribozymes
JP2006517109A (ja) 2003-02-07 2006-07-20 プロテイン デザイン ラブス インコーポレイテッド アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用
US8652787B2 (en) 2008-11-12 2014-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of ERBB4 as a prognostic and therapeutic marker for melanoma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2103323A1 (fr) * 1992-11-24 1994-05-25 Gregory D. Plowman Tyrosine kinase du recepteur her4 humain

Also Published As

Publication number Publication date
AU3963295A (en) 1996-05-06
JPH10507362A (ja) 1998-07-21
WO1996012019A2 (fr) 1996-04-25
EP0787187A1 (fr) 1997-08-06
NO971686L (no) 1997-06-16
WO1996012019A3 (fr) 1996-08-15
NO971686D0 (no) 1997-04-11
CA2202533A1 (fr) 1996-04-25
MX9702664A (es) 1997-06-28
IL115642A0 (en) 1996-01-19
FI971532A0 (fi) 1997-04-11

Similar Documents

Publication Publication Date Title
NO934163D0 (no) HER4 human reseptor-tyrosinkinase
DE69511950D1 (de) Entkuppelbares selbstblockierendes Abseilgerät
DE69221863D1 (de) Entfernbare, wärmerückstellbare gewebestützvorrichtung
FI88629B (fi) Beklaednad foer en arkformningsdel av en pappersmaskin med ytterligare, loepande tvaertraodar som har en stoerre modellaengd
DE69019550D1 (de) Piperidin-Derivate, ihre Herstellung und ihre Verwendung.
DE19681389T1 (de) Dosierungsform, umfassend Oxybutynin
MX9204425A (es) Derivados de quinazolina como inhibidores de la acetilcolinesterasa.
IT8948696A0 (it) Composizione orale antibatterica, antiplacca, antitartaro
DK0884964T3 (da) Stol, navnlig en kontorstol
DE3789559D1 (de) Menschlicher präproinsulinähnlicher Wachstumsfaktor I.
DE59208576D1 (de) 3-Isoxazolylphenylverbindungen, ihre Herstellung und ihre Verwendung
DE69204909D1 (de) Amino-Urazilderivate, deren Herstellung und Verwendung.
FI971532A (fi) HER4, ihmisen reseptorityrosiinikinaasi, joka kuuluu ryhmään ihokasvutekijäreseptorit
DK0763535T3 (da) Piperidinylmethyloxazolidin-2-on-derivater, deres fremstilling og deres anvendelse som centralnervesystem-aktive forbindelser
IT1227503B (it) Scaldabevande, specialmente per impiego domestico
NO920650D0 (no) Stol, spesielt kontorstol
FI922508A0 (fi) Pao en vattenhaltig vaetska baserad tvaettmedelskomposition med lineaer viskoelastisitet, avsedd foer auto- matiska diskmaskiner.
DE69002865T2 (de) Orale Zubereitung.
MX25777A (es) N-hateroaril-4-quinolinaminas, un procedimiento para su preparacion y su uso como medicamentos.
MX9100070A (es) Compuestos diazoicos,procedimientos para su preparacion y su utilizacion como colorantes
DE69008085T2 (de) Oxetanocinderivate, ihre Salze und ihre Verwendung.
DK32487A (da) 2,4-diamino-6-halogenalkylpyrimidiner, fremgangsmaade til deres fremstilling og deres anvendelse som herbicider
MX9200764A (es) Procedimiento para la preparacion de 3-hidroxipropanonitrilos 3-substituidos.
IT8906976V0 (it) Gruppo oscillante per sedie.
ZA9810425B (en) Novel heterocyclically substituted Ó-hydroxycarboxylic acid derivatives, their preparation and use as endothelin receptor antagonists.

Legal Events

Date Code Title Description
MA Patent expired